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Introduction
The non-obese diabetic/severe combined immunodeficient (NOD/SCID) xenotransplantation assay is currently the model of choice for assessment of transplantable human hematopoietic stem cells (HSC). This approach has been crucial to our understanding of human hematopoiesis; providing reliable determination of the phenotypes of repopulating cells 1 , and elucidating previously undescribed HSC populations. 2 More recently, a novel mouse strain has been developed by backcrossing β2 microglobulin-null (B2m-/-) mice onto the NOD/SCID background.
The resulting B2-/-NOD/SCID strain, in addition to the B-cell, T-cell, complement and partial NK defects that define the NOD/SCID model, has a complete lack of NK cell activity. 3 Hence, this model is reportedly even more permissive to xenotransplantation than the original NOD/SCID strain. 4 Acute myeloid leukemia (AML) is characterized by a relentless accumulation of immature, abnormal hematopoietic cells in the bone marrow and peripheral blood.
It has been postulated that AML is a disease maintained by leukemic stem cells and may be organized in a similar way to normal hematopoiesis. Indeed, only a subset of AML cells are capable of forming colonies in vitro and a smaller fraction can maintain colony production for six weeks whilst on feeder layers 5 . Definitive proof that a small population of leukemic stem cells produce the AML blasts, comes from six-week primary and secondary engraftment experiments in NOD/SCID mice 6 .
Further studies have revealed that these SCID-Leukemia initiating cells (SL-IC) share many properties with normal HSC, namely phenotype, quiescence, and in vitro CXCR-4 mediated migration. [6] [7] [8] AML is an extremely heterogeneous disease and since there are so many different known genetic abnormalities (and probably many more unknown), AML may be thought of as a collection of different diseases that have the same myeloid morphology. Indeed, for patients less than 60 years of age the single most important prognostic factor is the karyotype. 9,10 AML cases are currently divided via karyotype into the treatment groups of poor, intermediate and favorable prognosis. The majority of patients have an intermediate risk karyotype and the outcome of these patients is variable as well as difficult to predict using prospective tests.
Previous studies have reported that approximately 70% of AML cases will engraft in the NOD/SCID assay. 11 Although many groups have utilized the For personal use only. on April 20, 2017. by guest www.bloodjournal.org From NOD/SCID assay, the majority have only assessed the AML cases capable of engraftment. [12] [13] [14] [15] Few studies have addressed the variables that affect engraftment itself. 16 Various factors affecting normal hematopoietic cell engraftment have been identified and may be applicable to AML NOD/SCID engraftment.
A complex series of interactions of adhesion molecules, cytokines, chemokines and their receptors is responsible for the homing of transplanted human hematopoietic cells from the peripheral injection site to the bone marrow. 17 A major role in hematopoietic cell homing is attributed to the interaction between the chemokine SDF-1 and its receptor CXCR-4. 18 Overexpression of CXCR-4 on human CD34 + cells results in an increased ability to home to and engraft NOD/SCID marrows. 19 Furthermore, antibody blocking studies have revealed that engraftment of human hematopoietic cells in NOD/SCID mice is dependent on the interaction between CXCR-4 and SDF-1. 20 In AML, although both in vitro transendothelial migration and the level of in vivo NOD/SCID bone marrow homing are dependent on CXCR-4, it is not clear whether the actual ability to engraft NOD/SCID mice is dependent on the CXCR-4/SDF-1 axis. 8, 21 Here, we examined 59 AML patients for their ability to initiate leukemia in NOD/SCID mice. We established via morphology, phenotype, genotype and RNA expression that when AML engrafted, the AML produced was very similar to the patients' disease. We then investigated variables known to affect normal cell engraftment for their ability to cause AML engraftment. Increasing the cell dose, more intensive conditioning, more permissive recipients and alternative tissue sources (bone marrow), did not cause AML engraftment in previously non-engrafting AML samples. Both the CXCR-4 expression and in vivo homing of AML cells were the same between engrafters and non-engrafters. FLT-3 ITD and nucleophosmin mutations occurred at a similar frequency in engrafters and non-engrafters. The only variable, which did seem to be related to engraftment ability, was the karyotype of individual AML cases. Interestingly, follow-up of younger (< 60 years) intermediaterisk AML cases revealed a statistically significant difference in overall survival between NOD/SCID-engrafting and non-engrafting cases of AML.
Hence, the NOD/SCID assay appears to reproduce an AML very similar to the patients' disease and the ability to engraft seems to be an inherent property of AML cells, that is independent of homing, conditioning or cell dose/source, but is directly related to prognosis. Mice. All animal experiments were performed in compliance with Home Office and institutional guidelines. NOD/SCID mice and B2-/-NOD/SCID mice were originally obtained from Dr Leonard Schultz (Jackson Laboratory, Bar Harbour, ME, USA) and bred at Charles Rivers, Laboratories, UK. They were kept in micro-isolators and fed sterile food and acidified water. Mice aged 8-12 weeks were irradiated at 375 rads ( 137 Caesium source) up to 24 hours before intravenous injection of cells.
CXCR-4 expression analysis
Cells were stained with either phycoerythrin (PE)-conjugated or allophycocyanin (APC)-conjugated anti-CXCR-4 antibodies with phycoerythrin-cyanin 5 (PE-Cy5)conjugated anti-CD34 antibodies for 30 minutes at 4 °C (all antibodies from Becton Dickinson (BD) Biosciences (Oxford, UK)). Cells were washed and resuspended in phosphate buffered saline (PBS) with 2% FCS and 4,6-diamidino-2-phenylindoiole (DAPI). Cells were analyzed on a BD LSR flow cytometer. Gates were set up to exclude nonviable cells and debris. The negative fraction was determined using appropriate isotype controls.
Calcium Flux Measurement
Cells were labeled with 2.5μM Indo-1 (Invitrogen, CA) at 37C for 45mins. Cells were then analyzed on a BD LSR-II for 30 seconds to give background levels before stimulation with 100ng of stromal-cell derived factor -1 and analysis for a further 4 minutes. Analysis involved detection of fluorescence due to dye bound to Calcium (424/44nm filter used) and fluorescence due to unbound dye (530/30nm filter).
Analysis of murine bone marrow.
Six weeks after transplantation, mice were sacrificed by cervical dislocation. The femurs, tibias and pelvis were dissected and flushed with PBS. Red blood cells were lysed via ammonium chloride. Cells were For personal use only. on April 20, 2017. by guest www.bloodjournal.org From stained with human specific FITC-conjugated anti-CD19, PE-conjugated anti-CD33 and PE-Cy5-conjugated anti-CD45 antibodies. Dead cells and debris were excluded via DAPI staining. A BD LSR flow cytometer was used for analysis. More than 100,000 DAPI negative events were collected. Engraftment of AML was said to be present if a single population of CD45 + CD33 + CD19cells was present without accompanying CD45 + CD33 -CD19 + cells.
Assessment of engraftment potential of AML. Samples were screened to assess whether they had the potential to engraft NOD/SCID and B2-/-NOD/SCID mice. 10 7 MNCs were injected into each mouse. Engraftment of AML was confirmed, where possible, with morphology and fluorescent in situ hybridization on human cells FACSorted from engrafted murine marrows.
Fluorescence activated cell sorting (FACS). Murine marrow cells were suspended
in PBS with 2% FCS at 3 x 10 7 per ml and stained with human specific, anti-CD45-PE and murine specific anti-CD45-FITC. Cells were washed and resuspended in PBS with 2% FCS and DAPI before sorting on a MoFlo cell sorter (DakoCytomation Colorado Inc, Fort Collins, Colorado). Gates were set up to exclude nonviable cells (DAPI negative) and debris.
Fluorescent in situ hybridization
Briefly, FACSorted human cells were swollen in hypotonic (0.075M) KCL solution, fixed in Karnoy's fixative (3:1 methanol:acetic acid), before dropping onto clean, glass slides. Nuclei were "aged" overnight, before pepsin digestion, dehydration and application of fluorescent probes. Nuclei were incubated with probes overnight at 37°C before analysis at 1000x magnification on a Carl-Zeiss Axioplan-2 microscope equipped with Axiovision software.
Mutation detection
Deoxyribonucleic acid was extracted using standard phenol-chloroform methodologies. Primers and precise amplification conditions are available upon request and were derived from previously published studies (FLT3 exons 14-15 22 ;
FLT3 exon 20 23 ). Polymerase chain reaction products were sequenced directly by use Patients with an appropriate donor underwent allogeneic transplantation in first complete remission. No patents died form treatment related causes
Statistics
Logistic regression was used to assess the significance of factors involved in engraftment. Event free survival (EFS) was defined as survival with no evidence of persistent or recurrent disease. Patients with primary refractory disease (defined as bone marrow blasts greater than 5% in the marrow) were ascribed an EFS of 0 months. The actuarial probabilities of overall survival and EFS were plotted using the methodology of Kaplan and Meier as previously described. 25 No significant differences in the number of patients who underwent either treatment protocol could be found between NOD/SCID engrafting and non-engrafting AML cases (data not shown). The student's paired t-test for significance of no difference was used for all other assessments.
Affymetrix Array Analysis
Four samples, which gave high positive engraftment result, were processed for further microarray analysis (patients 9, 17, 19 and 37 in Table 1 ).
Details of RNA extraction, small sample cRNA target preparation, hybridization and microarray statistical analysis can be found in the Supplementary Methods.
Results

Not all Cases of AML Engraft in NOD/SCID mice
Ten million nucleated cells from 59 different AML patients were injected into NOD/SCID mice (Table 1) . Six weeks later, murine bone marrows were assessed via flow cytometry for the presence of human myeloid cells. As reported previously, we found that not all cases of AML can be reproduced in the NOD/SCID model 11 . We Patients marked with ψ were tested for Flt-3 mutations and were found to be negative. Prognosis risk group was defined as poor, intermediate or good via karyotype according to Grimwade et al 1998. 10 FK = failed karyotype at diagnosis. # = An abnormal stemline clone was detected in 2 out of 10 cells examined, containing a complex rearrangement between chromosomes 2, 10 and 11 resulting in insertion of 11q material in 10p12 with a breakpoint at 11q23. Presentation white blood cell (WBC) count is given as 10 9 cells/L. Patients in whom the WBC was less than 2 x 10 9 /L also had their bone marrow cells tested for engraftment capacity, with identical results to the peripheral blood data. All AML cases were assessed for NOD/SCID engraftment potential before any chemotherapy.
Engraftment in NOD/SCID mice reproduces AML
To confirm the leukemic nature of this myeloid (CD33 + /CD45 + /CD19 neg ) NOD/SCID engraftment, we compared the morphological features identified during diagnosis to the morphology of NOD/SCID engrafted cells. In all cases analyzed, the morphology of NOD/SCID engrafted cells was very similar to the original sample. A representative M2 AML is shown in Figure 1 . Similar to the diagnosis smear, a high proportion of the NOD/SCID engrafted cells were myeloblasts. Pathognomic AML Auer rods were also detectable in NOD/SCID mice, confirming the leukemic nature of these cells (arrowed in Figure 1B ). Wherever possible, we also performed FISH to detect characteristic genetic abnormalities in NOD/SCID engrafted cells (examples in Figure 1C -F). For personal use only. on April 20, 2017. by guest www.bloodjournal.org From Ten million cells were injected into NOD/SCID mice and marrows were analyzed for human, myeloid cell content six weeks later. (A) Diagnostic peripheral blood smear from an AML-M2 patient-10. (B) Murine marrow that was injected with cells from the same AML-M2 patient as Figure 1A . Myeloblasts, featuring Auer rods (arrowed) are present, indicating AML. (C) Dual fusion, dual colour fluorescent in situ hybridisation of a relapsed t [8, 21] AML-M2 sample. Cells positive for the rearrangement exhibit 1 green, 1 red and 2 orange spots. (D, E and F) Examples of NOD/SCID engrafted, FACSorted CD33 + /CD45 + cells, exhibiting AML-M2 t [8, 21] re-arrangement.
Figure 2: Gene expression analysis of engrafted AML cells.
Dendrogram is shown from the unsupervised hierarchical cluster analysis of the 8 chips for the 2,260 genes passing the variation filter. Independent of karyotype, AML patients were grouped between before and after engraftment. This means that the AML in the original patient is very much related to the AML that has grown in the mouse. The samples corresponding to before and after engraftment were always adjacent to each other, reflecting a very close relationship between them.
Gene Expression profile is extremely similar between engrafted AML cells and the original AML sample.
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To ensure that we were reproducing AML correctly in the NOD/SCID model, we examined the expression profiles of 8 AMLs (4 samples before engraftment and 4 samples after) by use of the oligonucleotide U133A arrays containing approximately 22,283 unique genes. An unsupervised hierarchical cluster analysis, performed on 2,476 or 2,260 genes passing the variation filter, grouped samples into 4 groups. On the basis of similarity in the expression pattern, the groups corresponded to the same patient sample before and after engraftment ( Figure 2 ). This indicates that the 2 sets of genes had expression patterns strongly associated with AML sample of origin.
The cluster dendrogram gave similar results with the 2 lists of genes, with or without the variation filter. A statistical group comparison approach was used to identify genes with statistically significant differences in expression levels between groups of samples before and after engraftment. By using a T-test analysis on normalized data, we could not identify any genes differentially expressed between before and after engraftment. Indeed, gene expression profiling on these samples showed highly consistent profiles. This was the same on normalized data directly or after logging (to log2) the normalized data.
Hence, expression profiling reveals no fundamental biological differences in acute myeloid leukemia samples before and after engraftment. Independent of karyotype, patients AMLs were grouped between before and after engraftment. The samples corresponding to before and after engraftment were always sitting adjacent to each others, reflecting a very close relationship between them. This means that the gene expression profile of AML in the original patient is very similar to the AML that has grown in the mouse.
Increasing the cell dose and utilizing alternative cell sources does not increase the number of engrafting AML samples.
To investigate factors that affect AML NOD/SCID engraftment, we repeated certain engraftment assessments, increasing the cell numbers and utilizing alternative tissue sources (bone marrow). Six-week NOD/SCID engraftment could not be achieved with up to 10 8 cells from five, previously non-engrafting AML samples.
Interestingly, although in two patients (53 and 59) AML engraftment was not observed with 10 7 cells, apparently normal multilineage engraftment was seen when 10 8 cells were injected. Taken together, these results suggest that the NOD/SCID 
Most cases of non-engrafting AML do not engraft in a more permissive xenotransplantation model
To investigate the influence of the murine microenvironment on AML engraftment, we examined engraftment in the more permissive B2-/-NOD/SCID model. Samples were injected into both the NOD/SCID assay and the B2-/-NOD/SCID model in paired experiments. Generally, samples that engrafted in the NOD/SCID assay, engrafted at higher level in the B2-/-NOD/SCID model. However, the majority (10/12) of AML cases that failed to engraft in the NOD/SCID model, could not be modelled in the B2-/-NOD/SCID assay. Only two samples (Patients 36 and 37), which failed to engraft in the NOD/SCID model, engrafted in the B2-/-NOD/SCID assay (Figure 3 ). Since the major difference between the B2-/-NOD/SCID and NOD/SCID models is probably NK cell activity, one may suggest that in most cases of AML, the reason for NOD/SCID non-engraftment is not immune mediated. 4 For personal use only. on April 20, 2017. by guest www.bloodjournal.org From
Figure 3: Most cases of non-engrafting AML do not engraft in the B2-/-NOD/SCID model. Ten million mononuclear cells from 23 different AML patients were injected into both NOD/SCID and B2-/-NOD/SCID mice in paired experiments.
Six weeks later, bone marrow engraftment was assessed via flow cytometry. AML engraftment was recorded if human CD33 + /CD45 + myeloid cells were present without an accompanying CD19 + /CD45 + B-cell population. 10 of 12 AML cases that failed to engraft in the NOD/SCID assay, did not engraft in the B2-/-NOD/SCID model. A lack of AML engraftment is not due to an obvious homing defect.
ENGRAFTERS
NON-ENGRAFTERS
To investigate the mechanism of homing, we first examined the expression of the CXCR-4 receptor on various NOD/SCID engrafting (n=11) and non-engrafting Figure   4 ).
We then looked directly at the homing of PKH-26 labelled AML cells to the marrows of NOD/SCID mice. Six million PKH-26 positive cells from 3 NOD/SCID engrafting and 4 non-engrafting AML cases were injected into NOD/SCID mice.
Sixteen hours later, murine marrows were assessed via flow cytometry for PKH26 bright cells. There was no significant difference (p=0.83) between engrafting groups in the proportion of labelled cells injected that homed to the marrow (data not shown, also confirmed in B2-/-NOD/SCID with patients 36 and 37). In addition for one sample (a B2-/-NOD/SCID-only engrafter, patient 37), the percentage of PKH26 bright cells that homed to the marrow was identical in B2-/-NOD/SCID and NOD/SCID, indicating that although they are not capable of six-week engraftment, cells still home to the NOD/SCID marrow. To confirm this result, we repeated the engraftment assessment of four previously non-engrafting samples, but injected the cells directly into the bone marrow as previously described 26 . In all four patients (46, 38, 43 and 35), no AML engraftment was observed.
When combined, these data suggest that the SL-IC from non-engrafting AML samples home normally to the marrow and that a lack of NOD/SCID engraftment is not due to an obvious homing defect.
Engraftment in NOD/SCID assay does not correlate with white blood cell count.
The level of engraftment in NOD/SCID mice is thought to correlate with white blood cell count within AML samples capable of NOD/SCID engraftment. 27 No study to date has investigated the relationship between the actual ability to engraft and the presentation white blood cell count. The median WBC in our study was very similar for cases capable and incapable of NOD/SCID engraftment (39.8 and 44.5 x 10 9 /L, respectively) and hence, no statistically significant difference could be detected.
Engraftment in NOD/SCID assay correlates with karyotypically defined prognostic group.
The samples we describe here represent a broad spectrum of AML cases,
including de novo and therapy related leukemia (tAML) from FAB groups 0, 1, 2, 3, 4 and 5. We excluded eight patients from karyotypic analysis, as five were relapse samples, two as the karyotype failed at diagnosis and one in which the karyotype was not performed. All of the remaining poor prognosis patients we analyzed engrafted in the NOD/SCID assay (5/5), whereas none of the previously untreated, good prognosis patients did (0/11 
There is no absolute correlation between two frequent mutations and NOD/SCID engraftment
To examine these two groups of AML cases further, we examined two genes that are frequently mutated in AML: Flt-3 and nucleophosmin. We detected the Flt3-ITD mutation in 6 (out of 29 tested) of our AML samples, a proportion similar to the For personal use only. on April 20, 2017. by guest www.bloodjournal.org From 18% that was previously published. 28 Four of these Flt3-ITD samples were capable of NOD/SCID engraftment and two were not (indicated by Δ in Table 1 ).
Nucleophosmin (NPM) is a nucleocytoplasmic-shuttling protein.
Approximately a third of normal karyotype AML cases (35%) have an abnormality in the C-terminus of the protein that causes it to be present in the cytoplasm of affected cells rather than restricted to the nucleus. 29 Although gene array analysis has revealed an upregulation of genes associated with stem cell function, 30 the NOD/SCID engraftment potential of this group remains to be determined. The most interesting aspect of abnormal nucleophosmin expression is that a subset of normal karyotype AML cases are identified. We tested 10 of our normal karyotype AML samples for the presence of the altered NPM gene. We found a higher proportion (7/10) of samples than has been previously reported (35%) contained the altered gene but this may be explained by our small number of samples (indicated by ⊥ in Table 1 ).
Consistent with previous reports, we did observe the co-incidence of 3/7 of our NPM mutations with Flt3-ITD (indicated by Δ⊥ in Table 1 ). 30 Within the ten patients analyzed, we cannot report a definite correlation with NOD/SCID engraftment (3/7 engraft in NOD/SCID mice).
Follow-up analysis confirms the relationship between NOD/SCID engraftment and disease behaviour
The majority of patients with AML have an intermediate risk karytotype.
Within this group are patients with AML that is refractory to treatment and actually have a poor prognosis. 10 The event-free survival data of 25 de novo, intermediate risk AML cases (<60 years old) that received intensive multi-agent chemotherapy is presented above. Four cases were censored at allograft in first complete remission (two patients in each group). NOD/SCID engrafting AML cases had a poor event-free survival when compared to non-engrafting AML cases, though this did not reach statistical significance.
Discussion
This work describes the assessment of primary human AML in NOD/SCID and B2-/-NOD/SCID mice. Via comparison to diagnostic smears, FISH and gene expression analysis we confirmed that both the NOD/SCID and B2-/-NOD/SCID assays reproduce the same AML as in the original patient. Although it has been reported that the phenotype of 10/16 AMLs changes during engraftment, this was at a different time-point of engraftment and hence may have represented cells derived from less primitive cells than those in our study. 4, 27 Contrary to previous studies which had investigated variables that affect the level of AML engraftment, 11,27,28 here, we studied the factors that are associated with whether or not individual AML cases engraft in the NOD/SCID model. We report here that approximately 50% of AML cases examined produced leukemic engraftment.
Since our results suggest that the inability of certain AMLs to engraft in the NOD/SCID model is not due to AML SL-IC frequency, immune rejection or tissue source, we progressed to examine the effect of homing. As mentioned above, the interaction between CXCR-4/SDF-1 plays a major role in hematopoietic cell homing in NOD/SCID mice. 17 We investigate here whether CXCR-4 expression and function was the same between NOD/SCID engrafting and non-engrafting AML cases. A recent study reports that within engrafting AML samples, homing to the marrow may be inhibited by anti-CXCR-4 antibodies. 21 The examination of the mean percentage of
CXCR-4 expression on CD34 + cells in our study is consistent with published values. 27
There was no statistically significant difference in CXCR-4 expression or in calcium release upon SDF-1 stimulation between NOD/SCID-engrafting and non-engrafting AML samples. Hence, when the process of homing is circumvented completely (direct BM injection), engraftment still cannot be achieved with previously nonengrafting AML samples, indicating that a homing defect is not the reason for the incapacity of some AML samples to engraft in NOD/SCID mice.
Since our results suggest that the reason that some AML samples do not engraft is independent of AML SL-IC frequency, CXCR-4 expression/homing or tissue source, we then tested for other potential correlations.
NOD/SCID engraftment correlated statistically with the karyotypically defined prognosis groups described by Grimwade et al. in 1998. 10 This is consistent with suggestions postulated by other authors working with AML and the NOD/SCID assay, but we can now confirm this association with a larger sample of consecutive, previously untreated, AML patients that were screened prospectively. 16 However, in this study, intermediate-risk AML cases that engrafted in the NOD/SCID assay had a poorer overall survival that was statistically significant when For personal use only. on April 20, 2017. by guest www.bloodjournal.org From compared to AML cases that were incapable of NOD/SCID engraftment. Hence, the NOD/SCID assay may be used to identify poor risk AML cases and in conjunction with array technology may be a useful tool to identify other pathogenic but subtle abnormalities within the intermediate risk AML group. Although many factors have been identified that affect the engraftment of hematopoietic cells in NOD/SCID mice, the most important factors may be the injected cells' self-renewal, proliferation and differentiation potentials. Cells that have limited potentials (such as CD34 + /CD38 + cells) cannot engraft at six weeks in the NOD/SCID model, whereas more primitive cells with greater cell potential (CD34 + /CD38 low/-) can still produce engraftment at six weeks. 1 Leukemic engraftment in the NOD/SCID model also discriminates between cells with a primitive (CD34 + /CD38 low/-) and mature (CD34 + /CD38 + ) phenotype, presumably due to the same intrinsic cellular factors. 6 It is extremely interesting to note that although the NOD/SCID model assesses AML independent of the response to chemotherapy, engraftment still correlates with the response to this treatment (prognosis group). A possible explanation is that NOD/SCID engraftment reflects the stem cell nature of each individual AML case.
AML cases that engraft in the NOD/SCID assay at six weeks may represent diseases driven by potent leukemia-initiating cells with stem cell-like self-renewal and proliferation abilities whereas non-engrafting AML cases may involve less potent leukemia-initiating cells with more restricted progenitor-type self-renewal and proliferation abilities.
Our data may give clues as to the cellular origin of the transformation event in individual AML cases. It is possible that AML cases that engraft in the NOD/SCID assay (and have a poor prognosis) are derived from a transformation in a hematopoietic stem cell whereas AML cases that do not engraft in the NOD/SCID assay (and have a more favorable prognosis) are derived from a progenitor-type cell.
The AML initiating cell in cases derived from normal stem cells may well inherit other biological properties that confer an increased chemoresistance when compared to AML cases in which the initiating cell is derived from a more progenitor-type cell.
Specifically, AML cases derived from normal stem cells would presumably have an increased ability to efflux and inactivate chemotherapy agents due an increased expression of various pumps and detoxification enzymes. Further studies examining this hypothesis are currently underway.
In conclusion, engraftment of AML in the NOD/SCID assay seems to be dependent on an inherent ability of the cells, which correlates well with disease prognosis.
